Novo Nordisk has announced a major reduction in the U.S. list prices (wholesale acquisition cost) of three of its widely prescribed semaglutide medicines — Wegovy, Ozempic and Rybelsus — as part of ongoing efforts to broaden access to these therapies for patients living with obesity and type 2 diabetes. The change takes effect January 1, 2027.
Under the new pricing, all doses of Wegovy, Ozempic and the oral formulation Rybelsus will carry a flat monthly list price of $675. For Wegovy, this represents roughly a 50 percent reduction from the current list price; for Ozempic, the reduction is around 35 percent. The adjusted pricing applies across the full range of doses for each medicine and is aimed at reducing barriers associated with high out-of-pocket costs tied to list prices for insured patients.
The company has framed this move as part of a broader initiative to make its semaglutide-based medicines more affordable, especially for people with high-deductible health plans or co-insurance benefit designs where the official list price directly affects what patients pay. This step builds on prior efforts, including savings offers and self-pay options, but the changes do not alter direct-to-patient self-pay prices outside of insurance.
Wegovy, Ozempic and Rybelsus contain semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used for various indications. Wegovy is prescribed for weight management, Ozempic for type 2 diabetes (including heart and kidney risk reduction), and Rybelsus as an oral treatment to improve blood glucose in adults with type 2 diabetes. These medicines are known for their broad clinical efficacy relative to others in the GLP-1 class.
The pricing revision arrives amid high demand for GLP-1 drugs and ongoing debate over medication affordability in the United States. Insurers, patients and policymakers have called for wider access and lower costs for chronic disease treatments, and Novo Nordisk’s announced list price shift reflects efforts to respond to that landscape.
